Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Deloitte
Accenture
Fish and Richardson
Johnson and Johnson
Farmers Insurance
McKinsey
Julphar
Colorcon

Generated: May 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,626,870

« Back to Dashboard

Which drugs does patent 6,626,870 protect, and when does it expire?

Patent 6,626,870 protects ELIGARD and is included in four NDAs.

This patent has nine patent family members in ten countries.
Summary for Patent: 6,626,870
Title: Stoppering method to maintain sterility
Abstract:A syringe assembly is provided which includes a hollow barrel that has an interior wall. The interior wall defines a chamber that retains medication. The hollow barrel also includes a distal end and a proximal end. The distal end of the hollow barrel has a passageway that is in contact with the chamber. The proximal end of the hollow barrel has an aperture. The syringe assembly also includes a primary plunger tip that is slidably positioned, in fluid tight engagement, with the interior wall. The primary plunger tip has a receptor to engage an engager of an elongated tip plunger rod. The syringe assembly also includes a secondary plunger tip that is slidably positioned, in fluid tight engagement, with the interior wall. The secondary plunger tip also has a receptor to engage an engager of a tip plunger rod. The secondary plunger tip is disposed between the primary plunger tip and the proximal end of the hollow barrel. The syringe assembly also includes a tip plunger rod, which facilitates operation of the secondary plunger tip, engaged to the secondary plunger tip. The present invention also provides a process for providing a lyophilized medication (i.e., lyophilizate) in a syringe assembly and also provides a process for reconstituting a medication in a syringe assembly.
Inventor(s): Yarborough; Cody L (Ft. Collins, CO), Duncan; Michael R. (Ft. Collins, CO), Norton; Richard L. (Ft. Collins, CO), Bawa; Rajan (Ft. Collins, CO), Madril; Dominic G. (Loveland, CO), Barrett; Christopher J. (Ft. Collins, CO)
Assignee: Artix Laboratories, Inc. (Fort Collins, CO)
Application Number:09/536,479
Patent Claim Types:
see list of patent claims
Process;

Drugs Protected by US Patent 6,626,870

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Tolmar Therap ELIGARD leuprolide acetate INJECTABLE;SUBCUTANEOUS 021343-001 Jan 23, 2002 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Tolmar Therap ELIGARD leuprolide acetate INJECTABLE;SUBCUTANEOUS 021379-001 Jul 24, 2002 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Tolmar Therap ELIGARD leuprolide acetate INJECTABLE;SUBCUTANEOUS 021488-001 Feb 13, 2003 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Tolmar Therap ELIGARD leuprolide acetate INJECTABLE;SUBCUTANEOUS 021731-001 Dec 14, 2004 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Federal Trade Commission
Medtronic
Chinese Patent Office
Deloitte
Covington
Express Scripts
US Department of Justice
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.